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Inability of vascular smooth muscle cells to
proceed beyond S phase of cell cycle, and
increased apoptosis in symptomatic carotid artery
disease
Ashwini S. Dhumea and Devendra K. Agrawal,a,b,c Omaha, Neb
Objective: Microemboli passing through the cerebral artery downstream from high-grade carotid artery stenosis produce
transient ischemic symptoms and may result in stroke. Rupture of carotid artery plaque is the main source of microemboli
in high-grade internal carotid artery stenosis. However, the mechanisms underlying plaque rupture are unclear. We
hypothesized that vascular smooth muscle cells (VSMC) from plaque in patients with symptoms of carotid artery stenosis
undergo increased apoptosis and decreased proliferation, compared with VSMC in patients without symptoms.
Methods: VSMC were isolated by means of enzymatic dissociation from plaque removed at carotid endarterectomy in
patients with symptoms of carotid artery stenosis, eg, hemispheric transient ischemic attacks, amaurosis fugax, or stroke,
and patients with high-grade stenosis without symptoms. VSMC were cultured and immunostained with smooth muscle
-actin and caldesmon antibodies to ensure purity. TUNEL assay and annexin V labeling were performed to identify
VSMC undergoing apoptosis. Proliferation assay with [3H] thymidine incorporation was performed in VSMC stimu-
lated with fetal bovine serum (FBS), and cell cycle profile was analyzed with DNA staining with Vindelov reagent.
Results: We isolated VSMC from symptomatic plaque that showed gross ulceration, and asymptomatic plaque. Apoptosis,
as measured with the TUNEL assay, in VSMC from symptomatic plaque was 5.45% 0.8%, and in asymptomatic plaque
was 1.20% 0.2%. Annexin V labeling revealed that 26.8% 3.8% cells were labeled for phosphatidylserine in VSMC in
symptomatic plaque, compared with 4.8%  0.3% cells in asymptomatic plaque. VSMC in asymptomatic plaque showed
significantly increased uptake of [3H] thymidine at all concentrations of FBS, compared with symptomatic plaque. In the
presence of 10% FBS, VSMC from asymptomatic plaque progressed through the S phase of the cell cycle, whereas
significantly increased numbers of VSMC from symptomatic plaque were arrested in the S phase.
Conclusion: Increased numbers of VSMC from symptomatic plaque undergo apoptosis, compared with VSMC from
asymptomatic plaque. This could be due to inability of VSMC from symptomatic plaque to progress beyond the S phase
of the cell cycle. Decreased proliferation and increased loss of VSMC as a result of apoptosis in symptomatic plaque may
result in plaque rupture, leading to development of symptoms. (J Vasc Surg 2003;38:155-61.)
Microemboli generated from ruptured plaque are the
main cause of cerebral symptoms in carotid artery disease.1
To ensure symptom-free survival, the challenge is not sim-
ply to suppress progression of atherogenesis but to suppress
symptoms caused by plaque rupture and ulceration in ex-
isting plaque. Three major determinants of plaque rupture
are necrotic core size and consistency of lipid burden,
fibrous cap thickness, and fibrous cap inflammation.2 A
lipid core occupying more than 40% of the plaque area3 and
a collagen-poor thin fibrous cap4 are predisposing factors to
plaque rupture. Ruptured fibrous caps have half as many
vascular smooth muscle cells (VSMC) and twice as many
macrophages as unruptured fibrous caps, indicating that
the ratio of VSMC to macrophages is greatly altered, and
the proportion of VSMC undergoing apoptosis is signifi-
cantly increased in plaque in patients with unstable versus
stable angina.4,5
VSMC are important in progression and stability of
atherosclerotic plaque. VSMC produce extracellular ma-
trix,6 which contributes to strength of the fibrous cap and
also is a vital component of the fibrous cap.7 Macrophages
and T-lymphocyte cytokines induce apoptosis in VSMC.8
Loss of VSMC may reduce plaque cellularity and limit
intimal thickening, which can also lead to rupture of the
fibrous cap and thrombosis.9 Rupture sites have low con-
centration of VSMC and increased concentration of mac-
rophages and inflammatory cells.10 Apoptosis of VSMC has
been detected in the shoulder regions of plaques, sites that
are predisposed to rupture.11 VSMC have the same potency
to generate thrombin as do platelets,9 by expressing phos-
phatidylserine (PS) on the cell surface and in the presence of
factor V and factor VII. PS acts as a substrate for thrombin
production.12 At present we have no evidence to support
our conjecture linking apoptosis of VSMC and plaque
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rupture, because of limitations in animal models of plaque
rupture and technical difficulties in identifying apoptotic
VSMC in complex atherosclerotic plaque.
Previous studies have reported increased apoptosis and
decreased survival of VSMC from advanced atherosclerotic
plaque compared with VSMC cultured from normal ar-
tery.13 However, VSMC from plaque in patients with and
without symptoms were not differentially examined. In this
study we tested our hypothesis that VSMC from symptom-
atic plaque had increased apoptotic and decreased prolifer-
ative profiles compared with VSMC from asymptomatic
plaque, causing consequent loss of VSMC in the fibrous cap
and leading to rupture.
MATERIAL AND METHODS
Patients and tissue collection
Tissue specimens were obtained from 4 patients with
symptoms and 4 patients without symptoms, as identified
from history and clinical examination performed by a vas-
cular surgeon. These patients had 70% to 98% carotid artery
stenosis and underwent carotid endarterectomy. Symptoms
included hemispheric transient ischemic attacks, amaurosis
fugax, or stroke. Time of collection of specimens from
patients with symptoms was within 2 weeks of onset of
symptoms. These plaques revealed ruptured fibrous caps
and ulcerated luminal surface. No intraplaque hemorrhage
was observed in any atherosclerotic plaque obtained from
patients either with or without symptoms. The necrotic
core of symptomatic plaque was considerably larger than
that in asymptomatic plaque. At histologic evaluation with
Gomori trichrome stain (data not shown), symptomatic
plaque revealed decreased cellularity, with equivalent stain-
ing for collagen, compared with asymptomatic plaque. We
reported increased immunoreactivity to CD68 in symp-
tomatic plaque compared with asymptomatic plaque.19
This observation suggested increased inflammation, pri-
marily due to macrophage accumulation, in symptomatic
plaque.
The Institutional Review Board of Creighton Univer-
sity approved the research protocol, and informed consent
was obtained from patients.
Smooth muscle cell isolation and culture
VSMC were isolated from plaques with elastase and
collagenase (Sigma, St Louis, Mo) digestion. VSMC from
symptomatic plaque proliferated slower than those from
asymptomatic plaque; the VSMC from asymptomatic
plaque had a doubling time of approximately 40 hours,
compared with approximately 60 hours for VSMC from
symptomatic plaque. Confluent cells showed the character-
istic hill-and-valley pattern associated with VSMC, and did
not form swirls, which are characteristic of fibroblasts.
Isolated cells were cultured serially in M199 media (Sig-
ma), and subcultured strains were used between passages 3
and 7. We decided to use the cells up to passage 7 on the
basis of changes in morphologic characteristics; after pas-
sage 7, VSMC from symptomatic plaque started to develop
a rounded, hypertrophied appearance rather than their
characteristic spindle shape. Purity of isolated VSMC was
tested with positive immunostaining to smooth muscle
-actin (MO815; Dako, Carpenteria, Calif) and caldesmon
(AM332-5M; Biogenex, San Ramon, Calif) (Fig 1). The
remaining VSMC in passage 3 were frozen and maintained
in liquid nitrogen for future use.
In-vitro apoptotic detection
TUNEL assay. VSMC were cultured in 25 cm2 flasks
and maintained for 24 hours in M199 medium and 0.5% to
1% fetal bovine serum (FBS). VSMC were then treated for
24 hours with either 2% or 10% FBS containing M199
medium. After 24 hours the cells were harvested with
trypsinization, with 0.25% trypsin and 1 mmol/L of ethyl-
enediaminetetraacetic acid (EDTA; Gibco/BRL, Grand
Island, NY). Cells were fixed in 1% paraformaldehyde for
15 minutes on ice, and washed twice with phosphate-
buffered saline solution (PBS). The cells were then perme-
abilized with ice-cold 70% ethanol for a minimum of 18 to
24 hours. All TUNEL assays were performed with an
apolipoprotein–bromodeoxyuridine kit (Apo-BRDU kit;
Pharmingen, San Diego, Calif). After washing the cells with
wash buffer, cells were resuspended in 50 L of labeling
solution in flow cytometry tubes. Labeling of cells was
terminated with centrifugation and washing of cells with
rinse buffer; then 100 L of anti BRDU–fluorescein iso-
Fig 1. Specificity of vascular smooth muscle cells from carotid
plaques for smooth muscle -actin and caldesmon. Cells were
isolated from atherosclerotic plaques of carotid artery and cul-
tured. After the third passage, cells were stained with hematoxylin-
eosin (A), smooth muscle -actin (B), and caldesmon (C). All the
cells showed immunopositivity to -actin and caldesmon, indicat-
ing that isolated cells were vascular smooth muscle cells, not
macrophages or myofibroblasts.
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thiocyanate (FITC) antibody solution was added to the
cells. After 30 minutes of incubation in the dark, propidium
iodide solution was added to cells. Flow cytometry was
performed within 3 hours. At least 10,000 cells in each
experimental group were analyzed in FACSCalibur (Bec-
ton-Dickinson, San Jose, Calif) with Lysis II software.
Annexin V labeling. For detection of PS externaliza-
tion, VSMC in culture were collected after the passage 3.
Adherent cells were washed twice with PBS (pH 7.4)
trypsinized with 0.25% trypsin and 1 mmol/L of EDTA.
The isolated cells in the medium were centrifuged at 1500
rpm for 10 minutes at 4° C. The pellet was resuspended in
5 mL of cold PBS and centrifuged. An annexin V–FITC kit
(Pharmingen) was used to measure PS externalization. The
incubation buffer (10 mmol/L of HEPES [N-2-hydroxy-
ethylpiperazine-N-2-ethanesulfonic acid]–potassium hy-
droxide [pH 7.5], 140 mmol/L of sodium chloride, 2.5
mmol/L of calcium chloride) was added to the cells, which
were then incubated in the presence of 10 g/mL annexin
V–FITC and 5g/mL of propium iodide for 15 minutes at
37° C. Labeled cells were analyzed with flow cytometry
with FACSCalibur and Lysis II software. In each experi-
mental group 10,000 cells were counted, and these events
were thought to represent at least 90% to 95% of the total
cell population.
Proliferation assay
VSMC were maintained in M199 medium containing
10%FBS. Cells were harvested, and 10,000 cells per well
were added to a 12-well plate. VSMC were maintained in
culture media supplemented with 10% FBS for 24 hours,
followed by culture in serum-deprived medium (M199
medium containing 0.5% to 1% FBS) for 24 hours. After
quiescent cells in the treatment groups received M199
medium conditioned with 2%, 10%, or 20% FBS, [3H]thy-
midine was added in the last 6 hours of the 24 hours of
conditioning. Cells were washed three times with PBS and
digested with 1 mL of 1N NaOH. Radioactivity in each
well was counted in a -scintillation counter and standard-
ized between groups with protein concentration.
Cell cycle profile
Cells were grown to 90% to 95% confluency and
trypsinized. The cells were then pelleted, resuspended, and
washed. Washed cells were passed through a cell sorter, and
the number of cells was determined. To every 1 105 cells,
1 mL of Vindelov reagent (containing Tris-buffered saline
solution, ribonuclease A [type IIA, 70 U/mg; Sigma], PI
[Sigma], nonidet P-40 [Sigma]) was added, and the cells
were placed in a tube covered with foil to protect against
light and placed in a refrigerator at 4° C. The cells were
analyzed in a flow cytometer to determine cell cycle phase
of each cell. Lysis II software was used to collect the data. In
each experiment, 10,000 cells were counted, and these
events are thought to represent at least 90% to 95% of the
total cell population. The area versus the width of the
fluorescent signal was analyzed to gate out cellular multi-
ples. Histograms of DNA content were analyzed with
Modfit Lt V1.01 (Verity Software House, Topsham, Me)
to determine fractions of the population in each phase of
the cell cycle (G0, G1, S, and G2/M).
Statistical analysis
Statistical analysis was performed with Prism 3.0
(Graphpad, San Diego, Calif). Data were calculated as
mean plus or minus standard error of the mean, and were
analyzed with the unpaired Student t test. Multiple com-
parisons were analyzed with analysis of variance to compare
individual experimental groups. P  .05 was considered
significant.
RESULTS
Apoptotic death in VSMC from asymptomatic and
symptomatic plaque. Cultured VSMCs from symptom-
atic plaque showed spontaneous apoptosis even in high
serum–containing medium, whereas VSMC from asymp-
tomatic plaque continued proliferation and survived in
low-serum media. Untreated VSMC consistently showed
minimal autofluoresence (1.3%-2.0%). Furthermore, in the
presence of annexin V–FITC or PI alone, there was a similar
pattern of autofluorescence (1.2%-2.6%). With M199 me-
dium with 10% FBS, the number of annexin V–positive cells
was significantly greater (P  .01) in VSMC isolated from
symptomatic plaque (26.8%  3.8%) compared with
asymptomatic plaque (4.8%  0.3%) (Table I). It was
difficult to measure apoptosis in VSMC from symptomatic
plaque maintained in M199 supplemented with 2% FBS,
because of excessive fragility of the cells and high cell
debris.
Annexin V labeling indicates initial response to apopto-
tic stimuli. To determine DNA fragmentation that occurs
during apoptosis, we performed the TUNEL assay to iden-
tify 3-OH nick ends of the DNA with deoxyuridine
triphosphate (dUTP) labeling. VSMC were grown under
similar culture conditions as described for annexin V label-
ing. VSMC from asymptomatic plaque had a significantly
higher (P .05) degree of dUTP labeling (5.45% 0.8%)
compared with VSMC from symptomatic plaque (1.20%
0.2%) (Table I).
Proliferation in VSMC from asymptomatic and
symptomatic plaque. Thymidine is an important compo-
nent of cell DNA, and when a cell proliferates it makes
Table I. Apoptotic index in vascular smooth muscle cells
from symptomatic and asymptomatic plaque
Apoptotic index*
TUNEL Annexin V
Asymptomatic 1.20  0.2 4.8  0.3
Symptomatic 5.45  0.8† 26.8  3.8†
*Calculated as ratio of immunostained cells (with dUTP in case of TUNEL
or annexin V antibody) to total number of cells times 100.
Ten thousand events were counted with flow cytometry. Values represent
mean  SEM (n 	 4) in each experimental group.
†P  .05.
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DNA to supplement two cells. Therefore, by measuring
incorporation of radioactive-labeled thymidine we can de-
termine whether the cells are actively proliferating or are
quiescent. These experiments were run in the isolated
VSMC of symptomatic and asymptomatic plaques. We
examined whether increasing the external stimuli for sur-
vival by supplementing the medium with higher FBS con-
centration would help the cells overcome apoptotic stimuli
and show greater proliferation.
We examined proliferation of VSMC under three con-
centrations of FBS: 2%, 10%, and 20% (Table II). In all
three concentrations of FBS there was significantly lower
thymidine incorporation in the VSMC of symptomatic
plaque compared with asymptomatic plaque. However, the
most striking difference was observed in 20% FBS– supple-
mented media (Fig 2) (P  .002). Further analysis of the
data revealed that VSMC of asymptomatic plaque contin-
ued proliferating with increasing concentration of FBS,
whereas proliferation of VSMC of symptomatic plaque
appeared to reach a plateau at 10% FBS (Fig 2).
Cell cycle profile of VSMC from symptomatic and
asymptomatic plaque. Our experiments in cell phase
analysis showed that VSMC from symptomatic plaque were
incapable of progressing through the cell cycle and could
not proceed beyond the S phase. Fig 3 shows representative
histograms of the DNA content of VSMC of symptomatic
and asymptomatic plaques after treatment for 48 hours
with M199 supplemented with 1% FBS. Under these se-
rum-deprived conditions, there was no significant differ-
ence in the fraction of cells in the S phase from asymptom-
atic plaque (41.3%  5.1%; Fig 3, A) and symptomatic
plaque (39.13%  3.20%; Fig 3, B). However, with serum
stimulation with 10% FBS, VSMC of asymptomatic plaque
proceeded through the S phase into the G2 phase, thereby
decreasing the number of cells in the S phase (10.48% 
4.2%; Fig 3, C). Of interest, there was no effect of 10% FBS
on number of VSMC from symptomatic plaque in the S
phase (40.8% 10.1%; Fig 3, D). Numbers of cells in the S
phase from symptomatic plaque were similar under condi-
tions of both serum stimulation and serum deprivation.
Table II. Cell proliferation and cell cycle profile in vascular smooth muscle cells from symptomatic and asymptomatic
plaque
Cell proliferation* (104 cpm) Cell cycle profile† (% VSMC)
2% FBS 10% FBS 20% FBS S phase 1% FBS S phase 10% FBS
Asymptomatic 10.6  0.5 16.4  0.3 24.4  1.4 39.1  3.2 10.5  4.2
Symptomatic 8.9  0.1‡ 13.9  0.3‡ 16.5  0.3* 41.3  5.1 40.8  10.1*
*Values represent mean  SEM (n 	 4).
†Values shown as percent number of cells in S phase as mean  SEM (n 	 4).
‡P  .05
Fig 2. Thymidine incorporation in VSMCs from asymptomatic and symptomatic plaques after stimulation with 2%,
10%, and 20% FBS for 24 hours in a 37°C humidified 5% CO2 incubator. Data are shown as the mean SEM from four
symptomatic and asymptomatic plaques. **P  .002 and *P  .05 (square represents asymptomatic VSMCs and
triangle represents symptomatic VSMCs).
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DISCUSSION
Apoptosis is tightly linked with the cell regulatory
pathway.14,15 Any defect or error in the cell regulatory
pathway results in apoptosis of the cell. Several studies have
reported on apoptotic cell death in VSMC cultured from
atherosclerotic coronary and aortic arteries.11,16,17 Apo-
ptosis in VSMC of carotid artery plaque has also been
identified, but no studies have been reported that compare
VSMC isolated from plaque of patients with symptomatic
and asymptomatic carotid stenosis.
According to the North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET) and the published
guidelines for carotid endarterectomy, patients with more
than 70% carotid stenosis and highly echogenic plaque are
ideal candidates for carotid endarterectomy.18 Patients
with or without symptoms might have similar stenosis
(
70%) in the carotid artery. However, it is unclear why in
one group of patients plaque ruptures and breaks off to
produce symptoms. Therefore the availability of plaque
from both asymptomatic and symptomatic patients offers
Fig 3. Cell proliferation profile of VSMCs from asymptomatic and symptomatic plaques. Representative histograms of
DNA content as stained with Vindelov’s reagent in VSMCs isolated from asymptomatic (A and C) and symptomatic (B
and D) plaques. VSMCs were incubated with 1% FBS (A and B) or 10% FBS (C and D) for 48 hours before measuring
the DNA content. The red peaks on each panel represent G0/G1 peak on the left and G2/M phases on the right. The
zone indicated by bars is the S phase. Based on their DNA content VSMCs collect in channels and the events in each
phase are recorded. The Y axis indicates the total events in each phase while the X axis is indicative of the cell cycle
phases. Please note a difference in the scale on the Y axis in A and C versus B and D.
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an excellent opportunity to investigate possible underlying
mechanisms that may drive stable asymptomatic plaque to
fissure or rupture. We reported a higher percentage of
apoptotic nuclei and a thinner fibrous cap in symptomatic
plaque compared with asymptomatic plaque.19 This sug-
gests that these factors might be involved in destabilizing
plaque, causing rupture and leading to symptomatic carotid
disease.
In this study we compared the apoptotic and cell pro-
liferative pathways in VSMC from symptomatic and asymp-
tomatic plaque. In our previous study we observed a higher
number of apoptotic cells in symptomatic plaque compared
with asymptomatic plaque. Because of limitation in identi-
fying the cell type undergoing apoptosis, we decided to
isolate and culture VSMC from plaque, because they have a
pivotal role in maintaining plaque stability. We observed
spontaneous death of VSMC from symptomatic plaque,
whereas VSMC from asymptomatic plaque remained viable
and continued proliferating. Furthermore, VSMC from
symptomatic plaque were difficult to maintain in culture
with minimum serum stimulation, indicating that growth
factor stimulation is required to maintain viability of VSMC
from symptomatic plaque. These data suggest that VSMC
from symptomatic plaque may have the intrinsic property
of undergoing apoptosis as a result of loss of telomerase
enzyme.20 Bennett et al13 reported similar observations in
VSMC cultured from advanced atherosclerotic lesions of
coronary arteries.
Apoptosis of VSMC is complex and has positive and
negative outcomes on progression of disease. Apoptosis of
VSMC leads to decrease in VSMC population, thereby
decreasing intimal thickening, as shown in animal mod-
els.21 On the other hand, loss of VSMC leads to decrease in
collagen production and thinning of the fibrous cap.22
Therefore, for stable plaque it is vital to have a balance in
programmed cell death and proliferation of VSMC.
To test whether VSMC from symptomatic plaque,
although they show a higher apoptotic index, are also
capable of undergoing proliferation, we performed a cell
proliferation assay. We observed that VSMC from asymp-
tomatic plaque had a healthier phenotype, with increased
thymidine incorporation with increased serum stimulation.
Although we observed a similar trend in VSMC from
symptomatic plaque, general incorporation of thymidine
by these cells was lower than that from asymptomatic
plaque. Although thymidine incorporation indicates that a
cell is capable of synthesizing DNA, it does not provide
evidence for completion of the cell cycle and resultant
mitosis. Therefore we performed analysis for cell cycle
profile.
Most VSMC from symptomatic plaque were arrested in
the S phase of the cell cycle, which could explain why we
observed an increase in thymidine incorporation without
efficient cell turnover. Thus the cell made enough DNA, as
measured by thymidine incorporation, but was incapable of
dividing into two cells. This suggests that VSMC from
symptomatic plaque had a dysfunction in the cell cycle
regulatory pathway, whereby the cells were capable of
being stimulated to enter the cell cycle but lacked the
internal machinery to carry the cell beyond the S phase.
This can be due to deficiency in the intermediate cell cycle
proteins, eg, cyclins and enzymes, required to proceed
through G2 and M phases.
23 Alternatively, since the cells
could have already reached senescence, further serum or
growth factor stimulation drives the cells to undergo apo-
ptosis.24
Atherosclerotic plaque and its components are com-
plex, and it is difficult to identify a single growth factor or
mitogen that can trigger apoptosis on senescent cells. We
previously reported that insulin-like growth factor–1
(IGF-1) has a major role in VSMC survival.25 It is therefore
possible that VSMC from symptomatic plaque have de-
creased density or affinity of IGF-1 receptors. Alternatively,
there could be a decreased receptor-response coupling
activation of IGF-1 receptors. In this regard, IGF-1 bind-
ing proteins and other factors within the transmembrane
signaling pathway may have a substantial role. This could
be supported by our preliminary studies, in which area of
immunoreactivity to IGF-1R antibody in necrotic core,
fibrous cap, and media was significantly greater in asymp-
tomatic plaque compared with symptomatic plaque (un-
published data).
Findings from our studies provide valuable insight into
the survival of VSMC. It is now imperative to unravel
events that condition VSMC from symptomatic plaque to
undergo apoptosis. There have been some reports that
VSMC express FasL24. VSMC express Fas receptor,24 and
therefore it will be interesting to identify expression of
Fas/FasL on VSMC from symptomatic and asymptomatic
patient plaque. Second, the question as to which apoptotic
pathway the cells choose for undergoing apoptosis will also
be a key factor in understanding apoptosis in VSMC iso-
lated from atherosclerotic plaque and in maintaining the
balance between apoptosis and proliferative responses,
which in turn may provide plaque stability.
In summary, data from this study suggest that increased
apoptosis of VSMC from symptomatic plaque is most likely
caused by arrest of the cells in the S phase, which could be
due to excessive cell cycling of VSMC or to loss of telom-
erase enzyme, leading to senescence. Increased apoptosis of
VSMC in symptomatic plaque could also be a result of
plaque rupture rather than an event preceding plaque rup-
ture. A better understanding of the pathways involved in
apoptosis of VSMC in carotid artery stenosis will provide
opportunities for development of more precise and cost-
effective treatment.
We thank Dr Tammy K. Ramos for providing us with
carotid endarterectomy specimens.
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